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1. VTE risk is high for newly diagnosed Myeloma patients receiving treatment and only 
modestly reduced by IMWG-guided thromboprophylaxis. 
2. VTE risk is equivalent for thalidomide and lenalidomide regimens, and in these 




Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs 
(IMiDs) are at high venous thrombosis (VTE) risk, but data are lacking from large prospective 
cohorts.  
 
We present thrombosis outcome data from Myeloma IX (n=1936) and Myeloma XI (n=4358), 
phase III randomized controlled trials for NDMM, treating transplant-eligible and ineligible 
patients before and after publication of thrombosis prevention guidelines.  
 
In Myeloma IX, compared to CTD (cyclophosphamide, thalidomide and dexamethasone), 
transplant-eligible patients randomized to CVAD induction (cyclophosphamide, vincristine, 
doxorubicin and dexamethasone) had higher VTE risk (22.5%(n=121/538) vs 
16.1%(n=89/554), aHR:1.46,95%CI:1.11-1.93). For transplant-ineligible patients, compared to 
MP (melphalan and prednisolone), patients randomized to CTDa (attenuated CTD) induction 
had higher VTE risk (16.0%(n=68/425) vs 4.1%(n=17/419), aHR:4.25,95%CI:2.50-7.20).  
 
In Myeloma XI, there was no difference in VTE or arterial thrombosis risk between transplant-
eligible pathways, CRD (cyclophosphamide, lenalidomide and dexamethasone) and CTD 
(VTE:12.2%(n=124/1014) vs 13.2%(n=133/1008), aHR:0.92,95%CI:0.72-1.18; arterial 
events:1.2%(n=12/1014) vs 1.5%(n=15/1008), aHR:0.80,95%CI:0.37-1.70). For transplant-
ineligible patients, there was no difference in VTEs between CRDa (attenuated CRD) and CTDa 
(10.4%(n=95/916) vs 10.7%(n=97/910), aHR:0.97, 95%CI:0.73-1.29). However, arterial risk 






Thrombotic events occurred almost entirely within 6m of treatment initiation. Thrombosis 
was not associated with inferior progression-free or overall survival (OS), apart from inferior 
OS for patients with arterial events (aHR:1.53, 95%CI:1.12-2.08) in Myeloma XI. The Myeloma 
XI trial protocol incorporated IMWG thrombosis prevention recommendations and compared 
to Myeloma IX, more patients were on thromboprophylaxis (80.5% vs 22.3%) with lower VTE 
rates for identical regimens (CTD:13.2% vs 16.1%, CTDa:10.7% vs 16.0%). However, 
thrombosis remained frequent in spite of IMWG-guided thromboprophylaxis, suggesting new 




Venous thrombosis (VTE) has a well-established association with cancer and is one of the 
leading causes of death in cancer patients.1 In addition to mortality risk, VTE is an important 
cause of long-term morbidity, impaired quality of life, adverse psychological impact and is a 
burden on health care resources.2,3 Multiple myeloma (MM) is the second most common 
blood cancer and is associated with a high VTE risk.4-7 A recent review of nearly 5,000 
myeloma patients showed those with VTE to be at an increased risk of mortality at two and 
five years after diagnosis, independent of other known prognostic factors.8 
 
A large retrospective study of over four million US veterans demonstrated a nine-fold 
increased deep vein thrombosis (DVT) risk in those with myeloma and a three-fold increased 
DVT risk in patients with Monoclonal Gammopathy of Uncertain Significance (MGUS).9 
Another large retrospective population-based study from Sweden demonstrated an increased 
VTE risk for patients with MM (adjusted hazard ratio (aHR) of 7.5, 4.6 and 4.1 at 1, 5 and 10 
years respectively after MM diagnosis), and to a lesser extent, patients with MGUS (aHR 3.4, 
2.1 and 2.1 at 1, 5 and 10 years respectively). Of interest, this group also showed an increased 
risk of arterial thrombosis for patients with MM (aHR 1.9, 1.5 and 1.5 at 1, 5 and 10 years 
respectively) and with MGUS (aHR 1.7, 1.3, 1.3 at 1, 5 and 10 years respectively).7  
 
The pathogenesis of VTE in MM is complex and only partially understood; patients can 




first year from diagnosis.6,9 The plasma cell cancer, its treatment and patient-related factors 
all contribute to the mechanism of thrombosis in MM.5,10 Treatments for MM have improved 
over the last decade with the introduction of immunomodulatory drugs (IMiDs) e.g. 
thalidomide, lenalidomide and pomalidomide. However, these drugs further increase VTE 
risk, as do corticosteroids which are included in most treatment regimens.11,12 Newly 
diagnosed MM (NDMM) patients receiving initial treatment with IMiD and high-dose 
corticosteroid are at high thrombotic risk, but there is a vast range of reported incidences 
from heterogeneous studies and a lack of data from large prospective patient cohorts. In 
addition, it is not known whether the two most commonly used IMiDs in induction therapy 
combinations, thalidomide and lenalidomide, have the same thrombotic risk as they differ in 
potency and side effect profile. Recently, myeloma specific VTE risk assessment scores have 
been developed and validated (IMPEDE VTE and SAVED).13-15 These scores help stratify VTE 
risk and may help identify patients who warrant thromboprophylaxis. The ability of the IMWG 
guidelines to discriminate VTE risk has been demonstrated in both the IMPEDE VTE and SAVED 
publications. 
 
The optimal thrombosis prevention strategy for patients with MM at high VTE risk remains 
controversial. Data from randomized trials suggest aspirin, LMWH and therapeutic warfarin 
reduce risk with an acceptable bleeding risk, but it is not clear which of these strategies is 
better.16-25 Emerging data suggest Apixaban thromboprophylaxis may be an option but this 
has not yet been compared to conventional approaches in a randomised trial.10,26-28  
 
In 2008, the International Myeloma Working Group (IMWG) published guidance on the 
prevention of IMiD-associated thrombosis in myeloma.12 These guidelines recommended that 
all patients should be risk assessed and offered LMWH thromboprophylaxis if they have ≥2 
thrombosis risk factors or if receiving concurrent IMiD and high-dose corticosteroid, whereas 
those with ≤1 risk factors be offered aspirin. More recent guidelines have made consistent 
recommendations.29,30 However, it is recognised that the guidelines are based on limited 
evidence and the expected risk reduction if they are implemented is unknown.30 It is also 
unclear how deliverable the recommendations are in the “real world”, for example whether 
daily LMWH injections are acceptable to patients and the logistics of initiating heparin is 





The MRC Myeloma IX and NCRI Myeloma XI trials are the largest randomized trials using IMiD 
and corticosteroid regimens for NDMM patients published to date. Myeloma IX recruited 
patients before the IMWG thrombosis prevention guidance and Myeloma XI recruited 




Trial design and treatment 
Myeloma IX and XI are phase III, UK-based, multicentre, open label, parallel group, 
randomized controlled trials for NDMM patients. Myeloma IX (ISRCTN684564111) recruited 
patients between May 2003 and November 2007. Myeloma XI (ISRCTN49407852) recruited 
patients between May 2010 and April 2016. The trials were approved by the national ethics 
review board (National Research Ethics Service, London, UK), institutional review boards of 
the participating centres, and the competent regulatory authority (Medicines and Healthcare 
Products Regulatory Agency, London, UK), and were undertaken according to the Declaration 
of Helsinki and the principles of Good Clinical Practice as espoused in the Medicines for 
Human Use (Clinical Trials) Regulations. All patients provided written informed consent. 
Inclusion criteria were similar in both trials and included adult patients with newly diagnosed 
and histologically confirmed symptomatic MM.  
 
Both trials had pathways for transplant-eligible and transplant-ineligible patients with 
pathway choice made by individual physician/patient based on patient’s performance status 
and co-morbidities, without age restrictions. Methods and results from both trials have been 
published previously.31-35 In brief, transplant-eligible patients in Myeloma IX were randomized 
between cyclophosphamide, thalidomide and dexamethasone (CTD) or cyclophosphamide, 
vincristine, doxorubicin and dexamethasone (CVAD) prior to autologous stem cell transplant 
(ASCT). Transplant-ineligible patients were randomized between attenuated CTD (CTDa) or 




randomization between thalidomide maintenance and observation in both pathways. All 
patients were also randomized to receive a bisphosphonate, either sodium clodronate or 
zoledronic acid.  
 
Transplant-eligible patients in Myeloma XI were randomized between CTD and 
cyclophosphamide, lenalidomide and dexamethasone (CRD). There was a second 
randomization for patients achieving a partial or minimal response between intensification 
with cyclophosphamide, bortezomib and dexamethasone (CVD) or no further therapy prior 
to ASCT. Patients with stable or progressive disease underwent intensification therapy prior 
to ASCT whilst patients with a very good partial response or complete response proceeded 
directly to ASCT. Transplant-ineligible patients were randomized between CTDa and 
attenuated CRD (CRDa). Transplant-ineligible patients also underwent the intensification 
randomization. Patients in both pathways were randomized between lenalidomide (+/- 
vorinostat) and observation. The induction randomization of the transplant-eligible pathway 
of the Myeloma XI trial was amended in June 2013 to include a randomization between the 
response-adapted approach described above (CTD/CRD +/- CVD) and the quadruplet 
carfilzomib, cyclophosphamide, lenalidomide and dexamethasone (KCRD). 
 
VTE prophylaxis 
The Myeloma IX trial protocol did not include specific thrombosis prevention 
recommendations, although it was stated that anticoagulation should be considered in those 
at high-risk for VTE with either warfarin or LMWH. In contrast, the Myeloma XI trial protocol 
incorporated IMWG thrombosis prevention guidance and specified that all patients should 
receive thromboprophylaxis for at least the first three months of treatment.12 It was 
recommended that low-risk patients should receive aspirin whereas high-risk patients should 






Collection of VTE and arterial events 
The objectives of this secondary analysis of Myeloma IX and XI were: to estimate the 
frequency, incidence and types of thrombosis events occurring on trial according to baseline 
characteristics, trial pathway and treatment; to investigate the thromboprophylaxis received 
prior to thrombosis events according to treatment and thrombosis risk category prior to the 
event; and to estimate the median progression-free survival (PFS) and overall survival (OS) 
according to thrombosis occurrence. 
 
 
In Myeloma IX, thrombotic events were collected from the adverse events (AE) case report 
form (CRF) and follow-up CRFs which included a thromboembolism section. In Myeloma XI, 
thrombotic events were collected from a specific thromboembolism CRF. Treatment CRFs also 
included indication of the occurrence of thromboembolism. For both trials, thrombosis events 




Analyses were carried out separately for each trial and pathway. In Myeloma IX, only VTEs 
were analysed due to the very low frequency of arterial events recorded (n=11). In Myeloma 
XI, both venous and arterial thrombosis were analysed. Analysis of patients receiving KCRD in 
Myeloma XI was performed using only patients contemporaneously randomized to CTD and 
CRD and included only VTE.  
 
Analyses were conducted using the safety population, which included all patients who 
received at least one dose of study treatment. This population classifies patients according to 
the treatment that they have received rather than to which they were randomized to receive. 
 
Baseline characteristics were compared between those experiencing and not experiencing a 




categorical baseline variables were evaluated with a chi-squared test; the non-parametric 
equivalent was used where appropriate. 
 
The Fine and Gray competing risks regression model compared the hazard of thrombosis 
events by treatment group accounting for the minimisation factors, excluding recruiting 
centre (Myeloma IX: haemoglobin, corrected serum calcium, serum creatinine and platelets; 
Myeloma XI: β2 microglobulin, haemoglobin, corrected serum calcium, serum creatinine and 
platelets), with unrelated death, defined as death without a preceding thrombosis event, 
specified as a competing risk. 
 
Person-years on trial was calculated as the sum of all patients, receiving at least one dose of 
study treatment, time in years from randomization to death or last date known to be alive. 
The incidence was calculated with the number of events as the numerator and the number 
of person-years on trial as the denominator. Confidence intervals for incidence were 
calculated using approximations to the Poisson distribution. 
 
Cumulative incidence function (CIF) curves of thrombosis events split by treatment group 
were estimated by non-parametric maximum likelihood estimation and compared by Gray’s 
test, accounting for unrelated deaths as a competing risk. 
 
Site of thrombosis, thrombosis risk and thromboprophylaxis were summarised in those who 
had an event. Thromboprophylaxis was also assessed in patients who had not had an event 
in Myeloma IX; this data was not available for Myeloma XI. 
 
PFS and OS were compared between those who did and did not experience a thrombosis 
event using the Kaplan-Meier method and Cox regression models and hazard ratios were 





Statistical analyses were performed using SAS (version 9.4). All reported p values are two-




The median follow-up after randomization for this analysis was 71 months (IQR:60-83 
months) in Myeloma IX and 60 months (IQR:48-77 months) in Myeloma XI. In both trials, the 
majority of the events occurred during induction (96.2% and 83.8% of events in Myeloma IX 
and Myeloma XI, respectively). The median time to first VTE in Myeloma IX was 2.2 months 
(IQR:1.31-3.44 months) and in Myeloma XI was 2.9 months (IQR:1.59-4.73 months). 
 
In the Myeloma IX trial, VTE occurred in 15.2% of all patients receiving treatment (368 events 
in n=295/1936), 19.2% (n=210/1092) of transplant-eligible patients and 10.1% (n=85/844) of 
transplant-ineligible patients.  
 
In the Myeloma XI trial, 13.7% of all patients receiving treatment suffered at least one 
thrombotic event ((746 events in n=599/4358), 12.2% (n=532) VTE and 1.8% (n=79) arterial 
thrombosis). Of note some patients suffered both VTEs and arterial events. Of transplant-
eligible patients, thrombotic events occurred in 14.7% ((n=371/2532), 13.4% VTE (n=340) and 
1.4% arterial (n=36)). Of transplant-ineligible patients, thrombotic events occurred in 12.5% 
((n=228/1826), 10.5% VTE (n=192) and 2.4% arterial (n=43)).  
 
There were a very small number of peri-transplant associated thrombotic events in both trials. 
In the 100 days after the administration of melphalan (autograft conditioning) there were 3 







The baseline characteristics for the safety population of patients within each trial and 
pathway are similar (supplementary Table 1). In both trials, transplant-eligible patients were 
younger than transplant-ineligible patients. 
 
In Myeloma IX, sex, age and paraprotein type were significantly different between patients 
who did and did not experience a VTE; no other characteristics differed (Table 1). Compared 
to patients who did not develop thrombosis, the patients developing thrombosis were 
younger, more likely to be female and more likely to have an IgG paraprotein. When the 
transplant-eligible and ineligible pathways were analysed separately, only paraprotein type 
differed in the transplant-eligible pathway and only sex differed in the transplant-ineligible 
pathway (supplementary Table 2). 
 
In Myeloma XI, β2 microglobulin and haemoglobin were significantly different between 
patients who did and did not experience a thrombosis event (Table 1). Compared to patients 
without thrombosis, the patients with thrombosis had a higher haemoglobin and lower β2 
microglobulin. When the transplant-eligible and ineligible pathways were analysed 
separately, sex, age, WHO performance status, β2 microglobulin, calcium, haemoglobin and 
light chain type were significantly different according to thrombosis incidence within the 
transplant-eligible pathway (supplementary Table 3). No baseline characteristics differed 
according to thrombosis incidence within the transplant-ineligible pathway. 
 
Thrombosis events according to treatment group 
In the Myeloma IX transplant-eligible pathway, there was a higher VTE risk in patients 
receiving CVAD than CTD (22.5% (n=121/538) vs 16.1% (n=89/554), aHR: 1.46, 95%CI:1.11-
1.93). For patients in the transplant-ineligible pathway, there was a higher VTE risk in patients 
receiving CTDa than MP (16.0% (n=68/425) vs 4.1% (n=17/419), aHR: 4.25, 95%CI:2.50-7.20). 




number of patients with VTE between the thalidomide maintenance and the observation only 
groups (1.5% (n=6/391) vs 1.7% (n=7/402), p=0.82). 
 
In the Myeloma XI transplant-eligible pathway, there was no difference in VTE risk between 
CRD and CTD (12.2% (n=124/1014) vs 13.2% (n=133/1008), aHR:0.92, 95%CI:0.72-1.18). In the 
KCRD treatment group, 16.3% (n=83/510) of patients experienced a VTE which was not 
significantly different to concurrently randomised patients receiving CRD (aHR:0.79, 
95%CI:0.53-1.18) or CTD (aHR:1.02, 95%CI: 0.7-1.47). For patients in the transplant-ineligible 
pathway, there was no difference in VTE risk between CRDa and CTDa (10.4% (n=95/916) vs 
10.7% (n=97/910), aHR:0.97, 95%CI:0.73-1.29). 
 
In the Myeloma XI transplant-eligible pathway, there was no difference in risk of arterial 
thrombosis between CRD and CTD (1.2% (n=12/1014) vs 1.5% (n=15/1008), aHR:0.80, 
95%CI:0.37-1.70). For patients in the transplant-ineligible pathway, there was a higher risk of 
arterial thrombosis in patients receiving CRDa than CTDa (3.1% (n=28/916) vs 1.6% 
(n=15/910), aHR:1.91, 95%CI:1.02-3.57).  
 
Within the maintenance phase, significantly more patients had a VTE in the lenalidomide 
maintenance group than the observation group although the absolute incidence was very low 
(4.1% (n=44/1082) vs 0.6% (n=5/889), p<0.0001). Arterial events were also more frequent in 
those receiving lenalidomide maintenance than observation (1.3% (n=14/1082) vs 0.3% 
(n=3/889), p=0.022). 
 
Incidence rate of thrombosis, comparison of equivalent treatment regimens in Myeloma IX 
and Myeloma XI trials 
The VTE incidence rate for patients receiving CTD was slightly higher in Myeloma IX than 




(95%CI:3.7-5.0)). The VTE incidence rate for patients receiving CTDa was higher in Myeloma 
IX than Myeloma XI (7.6 events/100PY (95%CI:6.2-9.5) vs 4.2 events/100PY (95%CI:3.4-5.0)). 
 
Cumulative incidence of thrombosis 
Across both trials, and all treatments, the cumulative incidence of VTE increases most rapidly 
during the first 6 months post-randomization, after which it plateaus (Figure 1). All plots in 
Figure 1 have been cut at 60 months because all curves remain unchanged after this point. 
 
In Myeloma IX, the 6-month VTE cumulative incidence was higher in the CVAD group than the 
CTD group (20.7% (95%CI:17.3%-24.1%) vs 15.0% (95%CI:12.0%-18.0%), Grey’s test p=0.006). 
Additionally, the 6-month VTE cumulative incidence was higher in the CTDa group than the 
MP group (15.6% (95%CI:12.1%-19.0%) vs 2.2% (95%CI:0.76%- 3.55%), Grey’s test p<0.0001). 
 
In Myeloma XI, the 6-month VTE cumulative incidence was comparable between treatment 
groups (10.7% for CRD (95%CI:8.77%-12.6%), 11.7% for CTD (95%CI:9.69%-13.7%), Grey’s test 
p=0.54). Additionally, there was no difference between the CIFs for KCRD, CRD and CTD 
(Grey’s test p=0.46). This was also the case within the transplant-ineligible pathway (8.7% for 
CRDa (95%CI:6.83%-10.5%) and 8.7% for CTDa (95%CI:6.83%-10.5%), Grey’s test p=0.82). 
 
For arterial events, the 6-month cumulative incidence was similar between groups in the 
transplant-eligible pathway (0.7% for CRD (95%CI:0.18%-1.21%) and 0.9% for CTD 
(95%CI:0.31%-1.48%), Grey’s test p=0.56), but in the transplant-ineligible pathway, the 6-
month cumulative incidence of arterial events was greater in the CRDa group than the CTDa 
group (2.2% (95%CI:1.25%-3.16%) vs 0.9% (95%CI:0.28%-1.52%), Grey’s test p=0.05) 







Within both trials and pathways, the most common sites of thrombosis were DVT and 
pulmonary embolism (PE) (Table 2). However, for patients randomized to CVAD, line 
associated VTE was the most common thrombosis site (37.1%, n=59/159 events), and line 
associated VTE was almost exclusively restricted to patients treated with CVAD (96.7% of all 
line associated VTEs in Myeloma IX). There were no other clear differences in the patterns of 
VTE presentations according to regimens. 
 
Thromboprophylaxis prior to Thrombosis 
In Myeloma IX, prior to the VTE event, 22.3% of patients received thromboprophylaxis (Table 
3). Where thromboprophylaxis was given, treatment dose warfarin was given most frequently 
and patterns of thromboprophylaxis were similar between treatment groups. Of the patients 
who did not develop VTE, 19.7% received thromboprophylaxis, with therapeutic warfarin 
given most frequently. 
 
In Myeloma XI, prior to the VTE event, 80.5% of patients received thromboprophylaxis (Table 
3). Where thromboprophylaxis was given, LMWH was given most frequently. Patterns of 
thromboprophylaxis were similar between treatment groups.  
 
VTE risk assessment prior to thrombosis 
In Myeloma IX, prior to thrombosis, 21.0% of patients had been assessed as high VTE risk and 
79.0% as low-risk, but the patterns of thromboprophylaxis were similar between these groups 
(Table 4). 
 
In Myeloma XI, prior to VTE, 54.7% had been assessed as high VTE risk and 45.3% as low-risk. 
Thromboprophylaxis was not given to 13.7% of high-risk patients and 20.7% of low-risk 




thromboprophylaxis and of these more received LMWH and fewer received aspirin than low-
risk patients (Table 4). 
 
Progression-free survival  
There was no difference in PFS for patients developing VTE compared to those who did not in 
either trial (Figure 2) (IX aHR:0.92, 95%CI:0.80-1.05; XI aHR:0.92, 95%CI:0.83-1.03). There was 
also no difference in PFS for patients developing arterial thrombosis in Myeloma XI compared 
to those who did not (supplementary Figure 3) (aHR:1.12, 95%CI:0.86-1.47).  
 
Overall Survival 
There was no difference in OS for patients developing VTE compared to those who did not in 
either trial (Figure 3) (IX aHR:0.87, 95%CI:0.74-1.02; XI aHR:0.90, 95%CI:0.78-1.04). In 
Myeloma IX, aHR for OS of patients with VTE remains virtually unchanged if results are 
adjusted for bisphosphonate allocation, zoledronate or clodronate (aHR of 0.88, (95%CI: 0.75-
1.03). In Myeloma XI, there was no bisphosphonate randomisation and patients received 
bisphosphonate as standard of care. 
 
In Myeloma XI, there was an increased mortality risk for patients developing arterial 
thrombosis (supplementary Figure 4) (aHR:1.53, 95%CI:1.12-2.08). 
 
Discussion 
Previous evidence from large retrospective cohorts has demonstrated that patients with 
myeloma are at increased risk of venous and arterial thrombosis, particularly in the first year 
after diagnosis.7,9 NDMM patients receiving initial treatment with IMiD and corticosteroid are 
at particularly high thrombotic risk.36 However, the range of reported incidences is very broad 
with unclear timing of risk, reflecting that the data arises from heterogeneous, relatively small 




Myeloma IX and XI are the largest randomized trials for first line treatment of NDMM patients 
using regimens that include IMiD with corticosteroid and therefore add significant new data 
to the literature. In addition, Myeloma IX and XI recruited patients before and after the IMWG 
VTE prevention guidance12 respectively, allowing indirect evaluation of the impact of these 
recommendations by comparison of identical regimens used in both trials.  
 
Both trials confirm and highlight the significant thrombosis risk for NDMM patients, with 
nearly all events occurring within 6 months of treatment initiation, regardless of treatment 
regimen. Data from Myeloma IX allows comparison between IMiD/corticosteroid containing 
induction to alternative regimens. For transplant-eligible patients, it is perhaps surprising that 
those treated without IMiD, using CVAD, had an even higher rate of thrombosis than those 
treated with CTD. The high thrombotic rate of CVAD for NDMM patients may in part relate to 
the high-dose dexamethasone and anthracycline chemotherapy (both known to contribute 
to VTE risk) but perhaps more importantly, the requirement of a long-term (3-6 months) 
central line for administration unlike the alternative “oral only” regimens. Of interest, in 
Myeloma IX, line related-VTEs were almost exclusively restricted to CVAD treated patients 
and represented 37.1% of VTE events in the CVAD group. For transplant-ineligible patients, as 
expected, thrombosis risk was far higher for the IMiD containing regimen, CTDa, than for MP, 
although even patients treated with MP, were at higher VTE risk than the expected 
background population (<1%/year).37 
 
Thalidomide and lenalidomide are the most commonly used IMiDs for myeloma treatment. 
Although structurally similar, lenalidomide is more potent with a different side effect profile 
and it was not previously known whether the two drugs had equivalent thrombotic risk. A 
recent retrospective cohort (n=2397) suggested the risk of venous and arterial events was the 
same for both drugs when used for NDMM patients with very few of these patients (<20%) 
receiving thromboprophylaxis.38 Data from Myeloma XI allows a direct comparison between 
lenalidomide and thalidomide treatment regimens for NDMM patients in a large prospective 
randomized NDMM patient cohort. In both transplant-eligible and ineligible patients, there 




regimens and no difference in arterial event rate with CRD vs CTD. Patients receiving CRDa 
had a higher rate of arterial thrombosis than those treated with CTDa but this needs to be 
interpreted with caution due to the low incidence of arterial events, which could also be 
affected by underreporting. 
 
In the Myeloma IX trial, thalidomide maintenance did not increase the risk of thrombosis but 
in contrast, in Myeloma XI lenalidomide maintenance increased the risk of venous and arterial 
thrombosis. However, thalidomide maintenance was only delivered for a median of 7 months 
in Myeloma IX, as many patients stopped prior to progression due to (non-VTE) toxicity.39 In 
contrast, within the lenalidomide maintenance phase of Myeloma XI, patients had a median 
of 18 cycles. Although lenalidomide increased the risk of thrombosis compared to 
observation, the absolute risk was low and far less than when used within induction as part 
of CRD or CRDa, probably due to the higher disease burden and additional corticosteroid in 
induction.  
 
Previous data on large retrospective cohorts demonstrated that arterial and venous 
thrombosis were associated with inferior survival in myeloma.40 In contrast to this, in both 
the Myeloma IX and XI trials, VTE events were not associated with an inferior OS. It is possible 
that this reflects differences between clinical trial and “real world” patient cohorts. Although 
both Myeloma clinical trials included a proportion of elderly patients with poor performance 
status within the transplant ineligible pathways, this may not reflect the full spectrum of 
frailty and comorbidity in non-trial patients. It is also important to recognise there may be 
other important adverse impacts of VTE such as chronic morbidity, impaired quality of life 
and psychological impact, but these have not been assessed in this study. In Myeloma XI, 
arterial events were associated with reduced OS, consistent with previous evidence. 
Thrombotic events (arterial or venous) did not adversely impact PFS, which suggests no 






Myeloma IX recruited patients prior to the IMWG thrombosis prevention guideline12 and 
accordingly there was no specific thrombosis prevention recommendation with only a 
minority of patients on thromboprophylaxis, predominantly with warfarin. Myeloma XI 
recruited patients after the IMWG guidance and the trial protocol contained consistent 
recommendations, with the majority of patients receiving thromboprophylaxis prior to 
thrombosis, predominantly with LMWH and aspirin rather than warfarin. When identical 
treatment regimens were compared between trials (CTD and CTDa), the risk of VTE was less 
in Myeloma XI compared to Myeloma IX. However, in spite of implementation of IMWG 
guidance and widespread thromboprophylaxis, VTE incidence remained high with only a 
modest reduction between trials. 
 
In both trials, patterns of thromboprophylaxis prior to VTE events did not significantly differ 
between treatment groups. Although in Myeloma XI, patients identified as high VTE risk prior 
to their event were more likely to be on preceding thromboprophylaxis, the differences in 
thromboprophylaxis patterns between high and low risk patients were surprisingly small. This 
suggests additional factors are considered when making thromboprophylaxis decisions, which 
may include patient and clinician choice, logistical difficulties with LMWH daily injections and 
bleeding risk. 
 
Overall, these findings suggest that patients with NDMM remain at unacceptably high VTE 
risk in spite of implementation of IMWG-guided thromboprophylaxis. Therefore, new 
approaches are needed, particularly in the initial 6 months of treatment. 
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Table 1. Myeloma IX and Myeloma XI baseline characteristics by VTE occurrence 
Characteristic 















Sex         


















Age         
























Ethnicity         









Black (black Caribbean, 
black African, other) 
1 (0.3%) 26 (1.6%) 27 (1.4%)  6 (1.0%) 69 (1.8%) 75 (1.7%)  
Asian (Indian, Pakistani, 
Bangladeshi, other) 
1 (0.3%) 14 (0.9%) 15 (0.8%)  5 (0.8%) 87 (2.3%) 92 (2.1%)  
Other 1 (0.3%) 15 (0.9%) 16 (0.8%)  4 (0.7%) 35 (0.9%) 39 (0.9%)  
Unknown 0 (0.0%) 0 (0.0%) 0 (0.0%)  8 (1.3%) 70 (1.7%) 78 (1.8%)  
WHO performance status         






















 102 (17.0%) 543 (14.4%) 645 (14.8%)  




 28 (4.7%) 178 (4.7%) 206 (4.7%)  
4 1 (0.3%) 21 (1.3%) 22 (1.1%)  3 (0.5%) 19 (0.5%) 22 (0.5%)  
Missing 1 (0.3%) 15 (0.9%) 16 (0.8%)  31 (5.2%) 189 (5.0%) 220 (5.0%)  
β2 microglobulin (mg/l)         
Mean (SD) 5.7 (5.10) 6.1 (6.02) 6.0 (5.89) 0.3240 4.8 (3.48) 5.3 (4.37) 5.2 (4.26) 0.0167 













Missing 27 135 162  221 1350 1571  














































Missing 12 55 67  0 1 1  
Calcium (µmol/l)         
Mean (SD) 2.4 (0.26) 2.4 (0.70) 2.4 (0.65) 0.3303 2.4 (0.21) 2.4 (0.25) 2.4 (0.25) 0.0826 













Missing 11 65 76  0 3 3  
Platelets (*10/l)         




























Missing 0 1 1  0 0 0  
Haemoglobin g/dl         
Mean (SD) 10.7 (1.86) 10.8 (3.43) 10.8 
(3.24) 
0.5868 11.1 (1.94) 10.7 (1.88) 10.8 (1.89) 0.0001 













Missing 0 1 1  1 1 2  
Paraprotein type         













 138 (23.0%) 938 (25.0%) 1076 
(24.7%) 
 
IgM 0 (0.0%) 8 (0.5%) 8 (0.4%)  1 (0.2%) 15 (0.4%) 16 (0.4%)  
IgD 9 (3.1%) 27 (1.6%) 36 (1.9%)  1 (0.2%) 34 (0.9%) 35 (0.8%)  
Non-secretor 6 (2.0%) 26 (1.6%) 32 (1.7%)  6 (1%) 20 (0.5%) 26 (0.6%)  




 81 (13.5%) 451 (12.0%) 532 (12.2%)  
Missing 2 (0.7%) 20 (1.2%) 22 (1.1%)  0 (0.0%) 5 (0.1%) 5 (0.1%)  
Light Chain Type         





































Missing 22 (7.5%) 141 (8.6%) 163 (8.4%)  9 (1.5%) 35 (0.9%) 44 (1.0%)  









Table 2. Myeloma IX and XI thrombosis by site 
 
Treatment received 





























































             
MP 2 (11.1%) 10 
(55.6%) 
















1 (1.0%) 0 (0.0%) 0 (0.0%) 6 (5.9%) NR     101 
(100%) 































































































































































































Table 3.  Myeloma IX and Myeloma XI thromboprophylaxis given prior to VTE and type of thromboprophylaxis received if given (by induction 
chemotherapy)  
 Myeloma IX Myeloma XI 
 CVAD CTD MP CTDa Total CTD CRD CTDa CRDa KCRD Total 
Thromboprophylaxis given            
Yes 44 (27.7%) 18 (16.7%) 3 (16.7%) 17 (20.5%) 82 (22.3%) 130 (79.8%) 132 (82.0%) 93 (84.5%) 93 (80.9%) 85 (75.2%) 533 (80.5%) 
No 114 (71.7%) 90 (83.3%) 15 (83.3%) 64 (77.1%) 283 (76.9%) 32 (19.6%) 27 (16.8%) 17 (15.5%) 21 (18.3%) 28 (24.8%) 125 (18.9%) 
Missing 1 (0.6%) 0 (0.0%) 0 (0.0%) 2 (2.4%) 3 (0.8%) 1 (0.6%) 2 (1.2%) 0 (0.0%) 1 (0.9%) 0 (0.0%) 4 (0.6%) 
Total 159 (100%) 108 (100%) 18 (100%) 83 (100%) 368 (100%) 163 (100%) 161 (100%) 110 (100%) 115 (100%) 113 (100%) 662 (100%) 
Thromboprophylaxis received (if given)*            
Aspirin NR NR NR NR NR 39 (28.9%) 46 (34.3%) 42 (43.3%) 39 (41.1%) 19 (21.6%) 185 (33.7%) 
Treatment dose warfarin 24 (54.5%) 9 (50.0%) 1 (33.3%) 13 (76.5%) 47 (57.3%) 5 (3.7%) 9 (6.7%) 3 (3.1%) 3 (3.2%) 2 (2.3%) 22 (4.0%) 
LMWH 16 (36.4%) 9 (50.0%) 2 (66.7%) 4 (23.5%) 31 (37.8%) 88 (65.2%) 76 (56.7%) 51 (52.6%) 52 (54.7%) 64 (72.7%) 331 (60.3%) 
Other 3 (6.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (3.7%) 3 (2.2%) 3 (2.2%) 1 (1.0%) 1 (1.1%) 3 (3.4%) 11 (2.0%) 
Missing 1 (2.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.2%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Total 44 (100%) 18 (100%) 3 (100%) 17 (100%) 82 (100%) 135 (100%) 134 (100%) 97 (100%) 95 (100%) 88 (100%) 549 (100%) 
* Not mutually exclusive 





Table 4. Myeloma IX and XI highest level of thromboprophylaxis given, by risk prior to VTE  
Thromboprophylaxis received 













Not given 42 (67.7%) 182 (78.1%) 224 (75.9%) 40 (13.7%) 50 (20.7%) 90 (16.9%) 
Aspirin NR NR NR 67 (23.0%) 80 (33.2%) 147 (27.6%) 
Treatment dose warfarin 9 (14.5%) 29 (12.4%) 38 (12.9%) 11 (3.8%) 3 (1.2%) 14 (2.6%) 
LMWH 9 (14.5%) 19 (8.2%) 28 (9.5%) 168 (57.7%) 100 (41.5%) 268 (50.4%) 
Other 1 (1.6%) 1 (0.4%) 2 (0.7%) 4 (1.4%) 5 (2.1%) 9 (1.7%) 
Missing 1 (1.6%) 2 (0.9%) 3 (1.0%) 1 (0.3%) 3 (1.2%) 4 (0.8%) 





Figure 1. VTE CIF curves for Myeloma IX transplant-eligible (A) and transplant-ineligible (B) pathways and Myeloma XI 
transplant-eligible (C), transplant-eligible including KCRD (D) and transplant-ineligible (E) pathways 
 
Figure 2. Progression free survival (PFS) by VTE occurrence in Myeloma IX (A) and Myeloma XI (B) 
 
Figure 3. Overall survival (OS) by VTE occurrence in Myeloma IX (A) and Myeloma XI (B) 
 
